Attend PACK EXPO – this year’s can’t-miss event in Chicago, Oct 23-26.
Discover solutions from 2,000+ exhibitors to advance your operations and network with colleagues at PACK EXPO International.
REGISTER TODAY

FDA Approves New Acute Migraine Drug

Eli Lilly’s new drug Reyvow relieves pain, nausea, and light sensitivity in within two hours of ingestion.

Migrane Drug Needed / Image: Getty
Migrane Drug Needed / Image: Getty

Migraines affect one in seven Americans, and are twice as prevalent in women versus men. If you’re not familiar with the affliction, it’s essentially a severe headache accompanied by nausea and sensitivity to light and sound. Thankfully, a recent CNBC article noted the FDA’s approval of a new drug from Eli Lilly that treats them quickly. Reyvow is the first drug to score approval in the first new drug class for migraines in two decades.

The FDA’s green light comes after two studies showed that patients who took the drug were more likely to have their migraine symptoms resolved after two hours than those who took placebos. Side effects reported by participants in the study include dizziness, fatigue, sedation, and paresthesia (a burning sensation in the skin), all of which I’d gladly take over a prolonged migraine.

Test Your Supply Chain Smarts
Take Healthcare Packaging's supply chain quiz to prove your knowledge!
Take Quiz
Test Your Supply Chain Smarts
Discover Our Content Hub
Access Healthcare Packaging's free educational content library!
Unlock Learning Here
Discover Our Content Hub